1. European Urology Oncology
Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials 
Guru P. Sonpavde, Gregory R. Pond, Karim Fizazi, Johann S. de Bono, Ethan M. Basch, Howard I. Scher, Matthew R. Smith 
European Urology Oncology 
DOI: /j.euo
Copyright © 2018 European Association of Urology Terms and Conditions

2. Fig. 1
Survival according to risk group quartile. There was no significant difference in survival between the cabozantinib and control arms stratified by prognostic risk group quartile.
European Urology Oncology DOI: ( /j.euo )
Copyright © 2018 European Association of Urology Terms and Conditions